The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease (Q28186354)

American Journal of Medicine

Europe PubMed Central

title

The role of adenosine 5'-diphosphate receptor blockade in patients with cardiovascular disease (English)

0 references

main subject

cardiovascular disease

1 reference

D J Solet

1

0 references

L R Zacharski

series ordinal

2

0 references

J F Plehn

series ordinal

3

0 references

language of work or name

English

0 references

publication date

July 2001

0 references

published in

0 references

volume

111

0 references

issue

1

0 references

page(s)

45-53

0 references

cites work

Aspirin response and failure in cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Development of aspirin resistance in persons with previous ischemic stroke.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Glycoprotein Ia/IIa-mediated activation-dependent platelet adhesion to collagen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

ADP-induced platelet activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Platelet membrane glycoproteins: functions in cellular interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

History of drugs for thrombotic disease. Discovery, development, and directions for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Effects of Aspirin on Angiotensin-Converting Enzyme Inhibition and Left Ventricular Dilation One Year After Acute Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Antiplatelet drugs. A comparative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Clinical pharmacokinetics of ticlopidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Bleeding time and antiplatelet agents in normal volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. The Ticlopidine Aspirin Stroke Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

The development of interventional cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

7 January 2021

Intracoronary stenting.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Clopidogrel as adjunctive antiplatelet therapy during coronary stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Clopidogrel versus ticlopidine after intracoronary stent placement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Effects of antiplatelet drugs on dialysis-associated platelet deposition in polytetrafluoroethylene grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Ticlopidine Treatment Reduces the Progression of Nonproliferative Diabetic Retinopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Thrombotic thrombocytopenic purpura associated with clopidogrel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Influence on lipoprotein metabolism of the platelet inhibitory drug ticlopidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Cardiac troponin T, creatine kinase, and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non–Q-wave myocardial infarctions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6

Results of CURE trial for acute coronary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2801%2900761-6